Cegedim Q3 2026 slides: business services surge as cloud unit drops

Cegedim reported Q3 2026 revenue of €155.9 million, up 1.5% reported and 1.2% like-for-like, while Cloud & Support revenue fell 40% after a major outsourcing contract expired; Business Services grew 9.5% to €47.6 million, supported by France’s e-invoicing reform. Management maintained full-year like-for-like growth guidance above 2% and projected higher recurring operating and operating income; related earnings-call coverage cited 2027 revenue growth guidance of 2%–5% and e-invoicing growth above 10%. Shares fell 2.09% to $10.3 after the presentation, amid modest overall growth, segment headwinds and uncertainty over a potential €4 million Ségur payment; net debt was projected to decline to approximately €130 million by year-end 2026 from €150 million at mid-year.

Analysis

The key question is whether Cegedim is converting revenue mix into durable free-cash-flow growth, not whether e-invoicing is growing. Expired Cloud & Support work can make reported growth look worse while helping margins only if the associated costs are genuinely removed or redeployed productively; management’s cost-redistribution explanation needs confirmation in segment profitability and cash conversion. Conversely, e-invoicing’s projected €5m EBIT contribution is not enough to underwrite a rerating without the base EBIT, implementation costs, customer retention and evidence that mandated adoption becomes recurring paid usage.

Near term, the full-year growth target requires a Q4 step-up from the nine-month run rate, leaving execution risk concentrated in one quarter. Over 1–3 months, verify Q4 trading, e-invoicing customer conversion and whether the €4m Ségur payment arrives on schedule; its delay would challenge the Cegedim Santé breakeven claim. Over 6–18 months, the upside case is a higher recurring-revenue mix and lower investment burden, while persistent pharmacy weakness and France concentration remain structural offsets. The contrarian opportunity is that investors may be treating Cloud’s contract expiry as purely demand destruction; it could be a low-quality revenue exit. But the stock’s weakness alone does not establish undervaluation, and management’s transition-year framing is not proof of margin improvement.

Key Decisions for Investors

• No immediate directional position: keep ALCGM on a catalyst watchlist rather than buying the share-price decline. The setup improves if Q4 confirms the >2% like-for-like growth target and reported operating income rises alongside recurring operating income.
• Consider a small, staged long only after evidence that e-invoicing growth is translating into paid recurring revenue and segment-level profitability, not just implementation activity. Reassess if growth misses guidance or management reduces the 2027 outlook.
• Track the next disclosures for Cloud & Support cost removal/redeployment, capex as a share of revenue, and operating cash flow versus investment. Failure to show improving cash conversion would falsify the margin-led transition thesis even if revenue mix improves.
• Treat the €4m Ségur payment as a specific timing alert: confirmation supports the stated Cegedim Santé breakeven path; a deferral into 2027 weakens near-term earnings quality. Do not capitalize the projected e-invoicing EBIT contribution without its cost base and group EBIT context.